RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Oxford Biodynamics PLC raised $12.5 million from GL Capital Group, a Shanghai private equity investor with a healthcare focus. OBD uses a proprietary platform, EpiSwitch™, to develop biomarkers based on chromosome conformation signatures, which allow early identification of disease-causing changes. GL Capital, which will own a 5% stake in Oxford Biodynamics, will be in charge of finding China partners for OBD’s products/services.
Source: China Biotoday
